The stock of Atara Biotherapeutics Inc (NASDAQ:ATRA) last traded at $0.57, up 13.22% from the previous session.
Data from the available sources indicates that Atara Biotherapeutics Inc (NASDAQ:ATRA) is covered by 8 analysts. The consensus rating among analysts is ‘Hold’. As we calculate the median target price by taking the range between a high of $28.00 and a low of $0.40, we find $2.90. Given the previous closing price of $0.51, this indicates a potential upside of 468.63 percent. ATRA stock price is now -55.00% away from the 50-day moving average and -73.62% away from the 200-day moving average. The market capitalization of the company currently stands at $58.30M.
In total, 4 analysts have assigned it a hold rating, and 2 have given it a buy rating. Brokers who have rated the stock have averaged $7.95 as their price target over the next twelve months.
With the price target reduced from $31 to $1, Mizuho Downgraded its rating from Buy to Neutral for Atara Biotherapeutics Inc (NASDAQ: ATRA).
In other news, Touchon Pascal, President and CEO sold 20,409 shares of the company’s stock on Nov 16. The stock was sold for $7,939 at an average price of $0.39. Upon completion of the transaction, the President and CEO now directly owns 655,496 shares in the company, valued at $0.37 million. An SEC document containing details of the transaction can be found on the SEC’s website. On Nov 16, EVP, Chief Medical Officer Joshi Manher sold 12,287 shares of the business’s stock. A total of $4,780 was realized by selling the stock at an average price of $0.39. This leaves the insider owning 171,284 shares of the company worth $97631.88. Insiders disposed of 186,805 shares of company stock worth roughly $0.11 million over the past 1 year. A total of 6.00% of the company’s stock is owned by insiders.
During the past 12 months, Atara Biotherapeutics Inc has had a low of $0.20 and a high of $5.64. The fifty day moving average price for ATRA is $1.2710 and a two-hundred day moving average price translates $2.1680 for the stock.
The latest earnings results from Atara Biotherapeutics Inc (NASDAQ: ATRA) was released for Sep, 2023. According to the Biotechnology Company, earnings per share came in at -$0.66, inline with analysts’ expectations of -$0.66. This compares to -$0.82 EPS in the same period last year. The net profit margin was -6390.31% and return on equity was -425.97% for ATRA. The company reported revenue of $2.14 million for the quarter, compared to $4.46 million a year earlier. Comparatively to last year’s same quarter, the company’s quarterly revenue fell -52.05 percent. For the current quarter, analysts expect ATRA to generate $11.55M in revenue.
